Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | September 24, 2026

Sep 24, 2026

•

3 min read

Biotech & Pharma Updates | September 24, 2026

🧬 FDA approves Eli Lilly's Onswik (insulin efsitora alfa-gobe) for type 2 diabetes in Ph3-backed once-weekly insulin, Eli Lilly, InnoCare Pharma partner on five unmet need targets, $100M upfront, $3.25B milestones, Merck & Co.'s (remigromig) meets primary endpoint in Ph2b/3 trial for diabetic macular edema, Wnt pathway agonist shows noninferiority

Christian Cuchapin, +1

Biotech & Pharma Updates | September 23, 2026

Sep 23, 2026

•

3 min read

Biotech & Pharma Updates | September 23, 2026

🧬 AstraZeneca's Trixeo (budesonide/glycopyrronium/formoterol fumarate dihydrate) gains EU approval for asthma following Ph3 success, Boehringer Ingelheim expands Variant Bio cardiovascular collaboration, adding $250M in potential milestones, Roche, Ionis Pharmaceuticals' (sefaxersen) meets Ph3 endpoint in primary immunoglobulin A nephropathy, supporting accelerated approval bid

Christian Cuchapin, +1

Biotech & Pharma Updates | September 22, 2026

Sep 22, 2026

•

4 min read

Biotech & Pharma Updates | September 22, 2026

🧬 Boehringer Ingelheim, Envisagenics sign $1B multi-year oncology collaboration leveraging AI RNA splicing platform SpliceCore, J&J's Caplyta (lumateperone) meets Ph3 primary endpoint in bipolar I disorder-associated manic episodes, Iambic Therapeutics files for IPO, advancing AI-driven HER2 inhibitor IAM1363 for solid tumors

Christian Cuchapin, +1

Biotech & Pharma Updates | September 21, 2026

Sep 21, 2026

•

3 min read

Biotech & Pharma Updates | September 21, 2026

🧬 Telix to acquire ITM for up to $2.35B, aiming to build radiopharmaceutical powerhouse, Ultragenyx wins FDA approval for Fayuvi (rebisufligene etisparvovec), first-ever gene therapy for Sanfilippo syndrome type A, China unveils five-year plan targeting 25% of global innovative drug approvals by 2030

Christian Cuchapin, +1

Biotech & Pharma Updates | September 17, 2026

Sep 17, 2026

•

3 min read

Biotech & Pharma Updates | September 17, 2026

🧬 Bayer's Kerendia (finerenone) wins third FDA approval for chronic kidney disease associated with type 1 diabetes, Novo, Orbis Medicines partner on oral macrocycle cardiometabolic therapies, up to $1.4B in milestones, Lisata Therapeutics merges with Marea Therapeutics in reverse merger, raising $225M after failed Kuva Labs acquisition

Christian Cuchapin, +1

Biotech & Pharma Updates | September 16, 2026

Sep 16, 2026

•

3 min read

Biotech & Pharma Updates | September 16, 2026

🧬 Novartis acquires Sironax's blood-brain barrier delivery platform for $125M, Sling Therapeutics raises $123M Series C to advance oral thyroid eye disease treatment, Circle Pharma raises $92.5M Series E to advance cyclin D1 inhibitor for breast cancer

Christian Cuchapin, +1

Biotech & Pharma Updates | September 15, 2026

Sep 15, 2026

•

3 min read

Biotech & Pharma Updates | September 15, 2026

🧬 GSK acquires Chimagen Biosciences' trispecific T cell engager for multiple myeloma, deal worth up to $750M, FDA approves Curium's Bexlutry (lutetium Lu 177 dotatate), first radioligand equivalent targeting somatostatin receptor for gastroenteropancreatic neuroendocrine tumors, Electra Therapeutics plans $325M IPO to fund late-stage sHLH trial

Christian Cuchapin, +1

Biotech & Pharma Updates | September 14, 2026

Sep 14, 2026

•

4 min read

Biotech & Pharma Updates | September 14, 2026

🧬 Scholar Rock's Isembyld (apitegromab) wins FDA approval for spinal muscular atrophy following Ph3 success, Novo Nordisk rebrands to Novo, repositions amid GLP-1 market struggles against Eli Lilly, GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) cuts death risk 54% in Ph3 relapsed small-cell lung cancer trial

Christian Cuchapin, +1

Long Form Content

Polymer-Peptides Hybrids: Grove Biopharma Targets Undruggable Diseases!

Sep 12, 2026

•

7 min read

Polymer-Peptides Hybrids: Grove Biopharma Targets Undruggable Diseases!

[Republished Feature] Grove Biopharma uses protein-like polymers to deliver peptides inside cells, opening the door to drug targets that have long been considered unreachable.

Anis Fahandej-Sadi

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | September 24, 2026

Biotech & Pharma Updates | September 23, 2026

Biotech & Pharma Updates | September 22, 2026

Biotech & Pharma Updates | September 21, 2026

Biotech & Pharma Updates | September 17, 2026

Biotech & Pharma Updates | September 16, 2026

Biotech & Pharma Updates | September 15, 2026

Biotech & Pharma Updates | September 14, 2026

Polymer-Peptides Hybrids: Grove Biopharma Targets Undruggable Diseases!

TLDR Biotech

FAQ

Media Partners